Orbivirus
- Nogales A, Villamayor L, Utrilla-Trigo S, Ortego J, Martinez-Sobrido L, DeDiego ML. (2021). Natural Selection of H5N1 Avian Influenza A Viruses with Increased PA-X and NS1 Shutoff Activity. Viruses 13(9):1760. doi: 10.3390/v13091760. Q2.
- Chiem K, López-García D, Ortego J, Martinez-Sobrido L, DeDiego ML, Nogales A. (2021) Identification of amino acid residues required for inhibition of host gene expression by influenza A/Viet Nam/1203/2004 H5N1 PA-X. J Virol.:JVI0040821. doi: 10.1128/JVI.00408-21
- Moreno S, Calvo-Pinilla E, Devignot S, Weber F, Ortego J, Brun A (2020) Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge. PLoS Negl Trop Dis 14(12): e0008942. doi.org/10.1371/journal.pntd.0008942
- Alonso C, Utrilla-Trigo S, Calvo-Pinilla E, Jiménez-Cabello L, Ortego J, Nogales A. (2020) Inhibition of Orbivirus Replication by Aurintricarboxylic Acid. Int J Mol Sci. 21(19):E7294. doi: 10.3390/ijms21197294.
- Calvo-Pinilla E, Marín-López A, Moreno S, Lorenzo G; Utrilla-Trigo S, Jiménez-Cabello L, Benavides J, Nogales A, Blasco R, Brun A, Ortego J. (2020) A protective bivalent vaccine against Rift valley fever and bluetongue. NPJ Vaccines 30;5:70. doi: 10.1038/s41541-020-00218-y.
- Calvo-Pinilla E, Marín-López A, Utrilla-Trigo S, Jiménez-Cabello L, Ortego J. (2020) Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design. Curr Opin Virol. 44:49–56 org/10.1016/j.coviro.2020.06.003.
- Marín-López A, Moreno S, Lorenzo G, Benavides J, Gilbert S, Nogales A, Ortego J. (2020) Heterologous combination of ChAdOx1 and MVA vectors expressing protein NS1 as vaccination strategy to induce durable and cross-protective CD8+ T cell immunity to bluetongue virus. Vaccines (Basel), 29;8(3):E346. doi: 10.3390/vaccines8030346.
- López-Gil E, Moreno S, Ortego J, Borrego B, Lorenzo, G Brun A. (2020). MVA vectored vaccines encoding Rift Valley fever virus glycoproteins protect mice against lethal challenge in the absence of neutralizing antibody responses. Vaccines (Basel), 12;8(1). pii: E82; doi: 10.3390/vaccines8010082.
- Marín-López A, Barreiro-Piñeiro N, Utrilla-Trigo S, Barriales D, Benavente J, Nogales A, Martínez-Costas J, Ortego J, Calvo-Pinilla E. (2020) Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus Ankara. Vaccine 22;38(4):882-889. doi: 10.1016/j.vaccine.2019.10.087.
- Hilimire T A, Nogales A, Chiem K, Ortego J, Martinez-Sobrido L. (2020) Increasing the Safety Profile of the Master Donor Live Attenuated Influenza Vaccine. Pathogens 9(2), 86; doi: 10.3390/pathogens9020086. Q2
- Jiménez-Cabello L, Utrilla-Trigo S, Calvo-Pinilla E, Moreno S, Nogales A, Ortego J, Marín-López A. (2020). Viral Vector Vaccines against Bluetongue Virus. Microorganisms 9(1):42. doi: 10.3390/microorganisms9010042. Q2
- Marín-Lopez A, Calvo-Pinilla E, Moreno S, Utrilla-Trigo S, Nogales A, Brun A, Fikrig E, Ortego J. (2019). Modeling arboviral infection in mice lacking the interferon Alpha/Beta Receptor. Viruses 11(1). pii: E35. doi: 10.3390/v11010035.
- Marín-López A, Calvo-Pinilla E, Barriales D, Lorenzo G, Brun A, Anguita J, Ortego J. (2018) CD8 T cell responses to an immunodominant epitope within the non-structural protein NS1 provides wide immunoprotection against bluetongue virus in IFNAR(-/-) mice. Virol. 31;92(16):e00938-18 DOI: 10.1128/JVI.00938-18.
- Calvo-Pinilla E, Gubbins S, Mertens P, Ortego J, Castillo-Olivares J. (2018) The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host. Antiviral Res. 154:132-139. Doi:10.1016/j.antiviral.2018.04.015.
- Lorenzo G, López-Gil E, Ortego J and Brun A. (2018). Efficacy of different DNA and MVA prime-boost vaccination regimens against a Rift Valley fever virus (RVFV) challenge in sheep twelve weeks following vaccination. Veterinary Research 49: 21 DOI : 10.1186/s13567-018-0516-z. Q1
- Aksular M, Calvo-Pinilla E, Marín-López A, Ortego J, Chambers AC, King LA, Castillo-Olivares J. (2018). A single dose of African horse sickness virus (AHSV) VP2 based vaccines provides complete clinical protection in a mouse model. Vaccine. pii: S0264-410X(18)31341-0. doi: 10.1016/j.vaccine.2018.09.065. Q1
- Pérez P, Q Marín M, Lázaro-Frías A, Jiménez de Oya N, Blázquez AB, Escribano-Romero E, S Sorzano CÓ, Ortego J, Saiz JC, Esteban M, Martín-Acebes MA, García-Arriaza J. A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice. (2018). Sci Rep. 8(1):17385. doi: 10.1038/s41598-018-35724-6. Q1.
- Marín-López A, Calvo-Pinilla E, Barriales D, Lorenzo G, Benavente J, Brun A, Martinez-Costas J, Ortego J. (2017). Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus. Antiviral Res 142:55-62. Q1
- Marín-López A, Barriales D, Moreno S, Ortego J, Calvo-Pinilla E. (2016). Defeating Bluetongue virus: new approaches in the development of multiserotype vaccines. Future Virol. 11(7):535-548. Q4
- Marín-López A, Bermúdez R, Calvo-Pinilla E, Moreno S, Brun A, Ortego J. (2016). Pathological characterization of IFNAR (-/-) mice infected with bluetongue virus serotype 4. Int. J. Biol. Sci. 12(12):1448-1460. Q2